Therapeutic targets of misguided T cells in systemic lupus erythematosus

Tsutomu Takeuchi, Kensei Tsuzaka, Hideto Kameda, Kouichi Amano

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

It is widely accepted that T cells with defective function play a central role in the pathogenesis of systemic lupus erythematosus (SLE). The detailed molecular mechanism underlying the aberrant function of SLE T cells is now being revealed. The TCR zeta chain, transcription factor, elf-1, inflammation signal transducer NF-kB, and PKC theta have been identified as the responsible molecules. In contrast to the defective signal transduction molecules, surface structures such as adhesion molecules, and co-stimulators have been reported to increase in their expression and function. Glucocorticoids and immunosuppressive agents have greatly improved the outcome of acute diseases and 5-year survival rate. However, it is suggested that long-term survival and quality of life appears to be unsatisfactory. Although the medical management of SLE is not sufficient to warrant long-term survival of young patients, recent progress in anti-cytokine biologics therapy against rheumatoid arthritis (RA) has facilitated searching for the molecular targets of SLE. In this report, we briefly review the molecular basis of SLE pathogenesis, and discuss possible therapeutic targets in this disease, focusing particularly on signal transduction and adhesion molecules in T cells.

Original languageEnglish
Pages (from-to)295-298
Number of pages4
JournalCurrent Drug Targets: Inflammation and Allergy
Volume4
Issue number3
DOIs
Publication statusPublished - 2005 Jun
Externally publishedYes

Fingerprint

Systemic Lupus Erythematosus
T-Lymphocytes
Signal Transduction
Therapeutics
Biological Therapy
Survival
NF-kappa B
Acute Disease
Immunosuppressive Agents
Transducers
Glucocorticoids
Rheumatoid Arthritis
Transcription Factors
Survival Rate
Quality of Life
Cytokines
Inflammation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pharmacology
  • Immunology

Cite this

Therapeutic targets of misguided T cells in systemic lupus erythematosus. / Takeuchi, Tsutomu; Tsuzaka, Kensei; Kameda, Hideto; Amano, Kouichi.

In: Current Drug Targets: Inflammation and Allergy, Vol. 4, No. 3, 06.2005, p. 295-298.

Research output: Contribution to journalArticle

Takeuchi, Tsutomu ; Tsuzaka, Kensei ; Kameda, Hideto ; Amano, Kouichi. / Therapeutic targets of misguided T cells in systemic lupus erythematosus. In: Current Drug Targets: Inflammation and Allergy. 2005 ; Vol. 4, No. 3. pp. 295-298.
@article{f1135ca5f5014b7db790868b93e682b1,
title = "Therapeutic targets of misguided T cells in systemic lupus erythematosus",
abstract = "It is widely accepted that T cells with defective function play a central role in the pathogenesis of systemic lupus erythematosus (SLE). The detailed molecular mechanism underlying the aberrant function of SLE T cells is now being revealed. The TCR zeta chain, transcription factor, elf-1, inflammation signal transducer NF-kB, and PKC theta have been identified as the responsible molecules. In contrast to the defective signal transduction molecules, surface structures such as adhesion molecules, and co-stimulators have been reported to increase in their expression and function. Glucocorticoids and immunosuppressive agents have greatly improved the outcome of acute diseases and 5-year survival rate. However, it is suggested that long-term survival and quality of life appears to be unsatisfactory. Although the medical management of SLE is not sufficient to warrant long-term survival of young patients, recent progress in anti-cytokine biologics therapy against rheumatoid arthritis (RA) has facilitated searching for the molecular targets of SLE. In this report, we briefly review the molecular basis of SLE pathogenesis, and discuss possible therapeutic targets in this disease, focusing particularly on signal transduction and adhesion molecules in T cells.",
author = "Tsutomu Takeuchi and Kensei Tsuzaka and Hideto Kameda and Kouichi Amano",
year = "2005",
month = "6",
doi = "10.2174/1568010054022060",
language = "English",
volume = "4",
pages = "295--298",
journal = "Current Drug Targets: Inflammation and Allergy",
issn = "1871-5281",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Therapeutic targets of misguided T cells in systemic lupus erythematosus

AU - Takeuchi, Tsutomu

AU - Tsuzaka, Kensei

AU - Kameda, Hideto

AU - Amano, Kouichi

PY - 2005/6

Y1 - 2005/6

N2 - It is widely accepted that T cells with defective function play a central role in the pathogenesis of systemic lupus erythematosus (SLE). The detailed molecular mechanism underlying the aberrant function of SLE T cells is now being revealed. The TCR zeta chain, transcription factor, elf-1, inflammation signal transducer NF-kB, and PKC theta have been identified as the responsible molecules. In contrast to the defective signal transduction molecules, surface structures such as adhesion molecules, and co-stimulators have been reported to increase in their expression and function. Glucocorticoids and immunosuppressive agents have greatly improved the outcome of acute diseases and 5-year survival rate. However, it is suggested that long-term survival and quality of life appears to be unsatisfactory. Although the medical management of SLE is not sufficient to warrant long-term survival of young patients, recent progress in anti-cytokine biologics therapy against rheumatoid arthritis (RA) has facilitated searching for the molecular targets of SLE. In this report, we briefly review the molecular basis of SLE pathogenesis, and discuss possible therapeutic targets in this disease, focusing particularly on signal transduction and adhesion molecules in T cells.

AB - It is widely accepted that T cells with defective function play a central role in the pathogenesis of systemic lupus erythematosus (SLE). The detailed molecular mechanism underlying the aberrant function of SLE T cells is now being revealed. The TCR zeta chain, transcription factor, elf-1, inflammation signal transducer NF-kB, and PKC theta have been identified as the responsible molecules. In contrast to the defective signal transduction molecules, surface structures such as adhesion molecules, and co-stimulators have been reported to increase in their expression and function. Glucocorticoids and immunosuppressive agents have greatly improved the outcome of acute diseases and 5-year survival rate. However, it is suggested that long-term survival and quality of life appears to be unsatisfactory. Although the medical management of SLE is not sufficient to warrant long-term survival of young patients, recent progress in anti-cytokine biologics therapy against rheumatoid arthritis (RA) has facilitated searching for the molecular targets of SLE. In this report, we briefly review the molecular basis of SLE pathogenesis, and discuss possible therapeutic targets in this disease, focusing particularly on signal transduction and adhesion molecules in T cells.

UR - http://www.scopus.com/inward/record.url?scp=21044431923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044431923&partnerID=8YFLogxK

U2 - 10.2174/1568010054022060

DO - 10.2174/1568010054022060

M3 - Article

C2 - 16101536

AN - SCOPUS:21044431923

VL - 4

SP - 295

EP - 298

JO - Current Drug Targets: Inflammation and Allergy

JF - Current Drug Targets: Inflammation and Allergy

SN - 1871-5281

IS - 3

ER -